


# Uruguay

## Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-07-27)

### I. Key data on HPV and HPV-related cancers



Uruguay has a population of 1.42 millions women ages 15 years and older who are at risk of developing cervical cancer. Current estimates indicate that every year 402 women are diagnosed with cervical cancer and 175 die from the

disease. Cervical cancer ranks as the 3rd most frequent cancer among women in Uruguay and the 2nd most frequent cancer among women between 15 and 44 years of age. Data is not yet available on the HPV burden in the general population of Uruguay. However, in South America, the region Uruguay belongs to, about 12.1% of women in the general population are estimated to harbour cervical HPV-16/18 infection at a given time, and 62.6% of invasive cervical cancers are attributed to HPV types 16 or 18.

**Table 1. Crude incidence rates of HPV-related cancers**

	Male	Female
Cervical cancer	-	22.9
Anal cancer	1.3	1.4
Vulva cancer	-	2.1
Vaginal cancer	-	0.8
Penile cancer	2.0	-
Pharynx (excluding nasopharynx)	4.8	0.9


**Table 2. Burden of cervical cancer**

	Incidence	Mortality
Annual number of new cases/deaths	402	175
Crude rate	22.9	10.0
Age-standardized rate	18.9	7.1
Cumulative risk 0-74 years (%)	1.8	0.7
Ranking of cervical cancer (all years)	3rd	6th
Ranking of cervical cancer (15-44 years)	2nd	2nd

**Table 3. Burden of cervical HPV infection Uruguay**

	No. Tested	% (95% CI)
HPV prevalence in women with normal cytology	1119	19.8 (17.6-22.3)
HPV 16/18 prevalence:		
Normal cytology	1119	3.7 (2.7-4.9)
Low-grade cervical lesions	227	24.2 (19.1-30.2)
High-grade cervical lesions	-	--
Cervical cancer	-	--

**Figure 1. Comparison of the ten most frequent HPV oncogenic types in Uruguay among women with and without cervical lesions**



\*No data available. No more types than shown were tested or were positive.

# Uruguay

## Human Papillomavirus and Related Cancers, Fact Sheet 2017 (2017-07-27)

### II. Complementary data on cervical cancer prevention

**Table 4. Factors contributing to cervical cancer (co-factors)**

Smoking prevalence (%), women	21.1 [16.8-26.0]
Total fertility rate (live births per women)	1.9
Hormonal contraception use (%) (pill, injectable or implant), among women	23.9
HIV prevalence (%), adults (15-49 years)	0.5 [0.4 - 0.5]

**Table 5. Sexual behaviour**

MEN	
Percentage of 15-year-old who have had sexual intercourse	-
Range of median age at first sexual intercourse	-
WOMEN	
Percentage of 15-year-old who have had sexual intercourse	-
Range of median age at first sexual intercourse	-


**Table 6. HPV vaccine introduction**

HPV vaccination programme	National program
Date of HPV vaccination routine immunization programme start	2013

**Table 7. Cervical screening practices and recommendations**

Cervical cancer screening coverage, % (age and screening interval, reference)	40.0% (All women aged 30-64 screened every 3y, Comisión Honoraria de la Lucha Contra el Cáncer)
Screening ages (years)	21-69
Screening interval (years) or frequency of screens	3 years, after 2 consecutive annual negative tests

**Figure 2. Estimated coverage of cervical cancer screening in Uruguay, by age and study**



<sup>a</sup> Proportion of women in the total sample of the mentioned age range in the country or region that reported having a Pap smear during a given time period (e.g., last year, last 2, 3, 5 years or ever).

#### Contact information:

ICO/IARC HPV Information Centre  
 Institut Català d'Oncologia  
 Avda. Gran Via de l'Hospitalet, 199-203  
 08908 L'Hospitalet de Llobregat (Barcelona, Spain)  
[info@hpvcentre.net](mailto:info@hpvcentre.net)  
[www.hpvcentre.net](http://www.hpvcentre.net)